1
|
Guzmán-Porras JJ, Espitia Segura OM, Gómez Diaz LV. Recognizing red flags for alternative diagnoses in pediatric chorea beyond Sydenham's. Brain Dev 2024; 46:326-331. [PMID: 39317520 DOI: 10.1016/j.braindev.2024.08.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/03/2024] [Revised: 08/16/2024] [Accepted: 08/25/2024] [Indexed: 09/26/2024]
Abstract
BACKGROUND Chorea is a common movement disorder in children, requiring thorough clinical assessment and appropriate tests for etiological diagnosis. Early identification of treatable conditions can lead to effective treatment, reducing morbidity and improving quality of life. OBJECTIVE To describe the clinical, demographic, and epidemiological characteristics of children and adolescents diagnosed with chorea. METHODS A retrospective cross-sectional study of pediatric patients treated in a fourth-level hospital in Bogotá, Colombia, from January 2008 to January 2022. RESULTS 81 patients with chorea were found. The most frequent etiologies were rheumatic fever (50.6 %), vascular chorea (29.3 %), and chorea secondary to lupus (11.1 %). Patients with chorea secondary to rheumatic fever (Sydenham's chorea) were older compared to other etiologies, 10.36 ± 3.41 years vs 8.29 ± 5.16, p = 0.037. The presence of another movement disorder or abnormalities during the physical examination suggests a different etiology from rheumatic fever. Moreover, the presence of psychiatric symptoms was similar in all etiologies. However, a correlation between age and psychiatric symptoms was observed with an odds ratio of 1.14 95 % CI 1.02-1.29 per year. CONCLUSIONS Red flags in Sydenham's chorea suggesting an alternate etiology are younger age, the presence of other abnormal movements or other findings in the neurological exam or in the magnetic resonance imaging. No significant statistical differences were found between the etiologies with the presence of neuro-psychiatric manifestations. Nevertheless, these manifestations are very frequent in abnormal movements. This study evidenced the positive correlation between age and the presence of psychiatric symptoms.
Collapse
Affiliation(s)
- Jennifer J Guzmán-Porras
- Qualitative and Quantitative Research Network in Neuropediatrics (in Spanish RICCNeP), Colombia; Neuropediatric Department, HOMI Fundación Hospital Pediátrico la Misericordia, Bogotá, Colombia; Research Group "Neuroped-UNAL", Colombia; Medical School, Universidad Nacional de Colombia, Bogotá, Colombia.
| | - Oscar M Espitia Segura
- Qualitative and Quantitative Research Network in Neuropediatrics (in Spanish RICCNeP), Colombia; Neuropediatric Department, HOMI Fundación Hospital Pediátrico la Misericordia, Bogotá, Colombia; Research Group "Neuroped-UNAL", Colombia
| | - Lizeth V Gómez Diaz
- General Practice, HOMI Fundación Hospital Pediátrico la Misericordia, Bogotá, Colombia
| |
Collapse
|
2
|
Tarrano C, Galléa C, Delorme C, McGovern EM, Atkinson-Clement C, Brochard V, Thobois S, Tranchant C, Grabli D, Degos B, Corvol JC, Pedespan JM, Krystkowiak P, Houeto JL, Degardin A, Defebvre L, Beranger B, Martino D, Apartis E, Vidailhet M, Roze E, Worbe Y. Psychiatric phenotype in neurodevelopmental myoclonus-dystonia is underpinned by abnormality of cerebellar modulation on the cerebral cortex. Sci Rep 2024; 14:22341. [PMID: 39333780 PMCID: PMC11437022 DOI: 10.1038/s41598-024-73386-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2024] [Accepted: 09/17/2024] [Indexed: 09/30/2024] Open
Abstract
Psychiatric symptoms are common in neurodevelopmental movement disorders, including some types of dystonia. However, research has mainly focused on motor manifestations and underlying circuits. Myoclonus-dystonia is a rare and homogeneous neurodevelopmental condition serving as an illustrative paradigm of childhood-onset dystonias, associated with psychiatric symptoms. Here, we assessed the prevalence of psychiatric disorders and the severity of depressive symptoms in patients with myoclonus-dystonia and healthy volunteers (HV). Using resting-state functional neuroimaging, we compared the effective connectivity within and among non-motor and motor brain networks between patients and HV. We further explored the hierarchical organization of these networks and examined the relationship between their connectivity and the depressive symptoms. Comparing 19 patients to 25 HV, we found a higher prevalence of anxiety disorders and more depressive symptoms in the patient group. Patients exhibited abnormal modulation of the cerebellum on the cerebral cortex in the sensorimotor, dorsal attention, salience, and default mode networks. Moreover, the salience network activity was directed by the cerebellum in patients and was related to depressive symptoms. Altogether, our findings highlight the role of the cerebellar drive on both motor and non-motor cortical areas in this disorder, suggesting cerebellar involvement in the complex phenotype of such neurodevelopmental movement disorders.
Collapse
Affiliation(s)
- Clément Tarrano
- Paris Brain Institute, Sorbonne University - ICM, Inserm CNRS, Paris, F-75013, France
- Department of Neurology, Clinical Investigation Center for Neurosciences, Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Paris, France
- Department of Neurophysiology, Saint-Antoine Hospital, Paris, France
| | - Cécile Galléa
- Paris Brain Institute, Sorbonne University - ICM, Inserm CNRS, Paris, F-75013, France
- Centre de NeuroImagerie de Recherche (CENIR), Sorbonne Université, UMR S 975, CNRS UMR 7225, ICM, Paris, F-75013, France
| | - Cécile Delorme
- Paris Brain Institute, Sorbonne University - ICM, Inserm CNRS, Paris, F-75013, France
- Department of Neurology, Clinical Investigation Center for Neurosciences, Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Paris, France
| | - Eavan M McGovern
- Department of Neurology, St Vincent's University Hospital Dublin, Dublin, Ireland
| | - Cyril Atkinson-Clement
- Paris Brain Institute, Sorbonne University - ICM, Inserm CNRS, Paris, F-75013, France
- School of Medicine, University of Nottingham, Nottingham, UK
| | - Vanessa Brochard
- Department of Neurology, Clinical Investigation Center for Neurosciences, Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Paris, France
| | - Stéphane Thobois
- Department of Neurology, Hospices Civils de Lyon, Pierre Wertheimer Neurological Hospital, Expert Parkinson Center NS-PARK/FCRIN, Bron, France
- Marc Jeannerod Cognitive Neuroscience Institute, CNRS, UMR 5229, Bron, France
- University of Lyon, Université Claude Bernard Lyon 1, Faculté de Médecine et de Maïeutique Lyon Sud Charles Mérieux, Oullins, France
| | - Christine Tranchant
- Département of Neurology, Universitary Hospital of Strasbourg, Strasbourg, France
- Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), INSERM- U964/CNRS-UMR7104/ University of Strasbourg, Illkirch, France
- Fédération de Médecine Translationnelle de Strasbourg (FMTS), University of Strasbourg, Strasbourg, France
| | - David Grabli
- Department of Neurology, Clinical Investigation Center for Neurosciences, Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Paris, France
| | - Bertrand Degos
- Department of Neurology, Avicenne Hospital, Assistance Publique-Hôpitaux de Paris, Sorbonne Paris Nord, Bobigny, France
| | - Jean Christophe Corvol
- Paris Brain Institute, Sorbonne University - ICM, Inserm CNRS, Paris, F-75013, France
- Department of Neurology, Clinical Investigation Center for Neurosciences, Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Paris, France
| | - Jean-Michel Pedespan
- Department of Neuropediatry, Universitary Hospital of Pellegrin, Bordeaux, France
| | | | - Jean-Luc Houeto
- Department of Neurology CHU Limoges, EpiMaCT - Epidemiology of chronic diseases in tropical zone, Institute of Epidemiology and Tropical Neurology, Inserm U1094, IRD U270, Univ. Limoges, OmegaHealth, Limoges, France
| | - Adrian Degardin
- Department of Neurology, Tourcoing Hospital, Tourcoing, France
| | - Luc Defebvre
- , Troubles cognitifs dégénératifs et vasculaires, Lille, F-59000, France
- Lille Centre of Excellence for Neurodegenerative Diseases (LiCEND), University of Lille, CHU Lille, INSERM, Lille, U1172, F-59000, France
| | - Benoit Beranger
- Paris Brain Institute, Sorbonne University - ICM, Inserm CNRS, Paris, F-75013, France
- Centre de NeuroImagerie de Recherche (CENIR), Sorbonne Université, UMR S 975, CNRS UMR 7225, ICM, Paris, F-75013, France
| | - Davide Martino
- Department of Clinical Neurosciences, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada
- Hotchkiss Brain Institute, University of Calgary, Calgary, AB, Canada
| | - Emmanuelle Apartis
- Paris Brain Institute, Sorbonne University - ICM, Inserm CNRS, Paris, F-75013, France
- Department of Neurophysiology, Saint-Antoine Hospital, Paris, France
| | - Marie Vidailhet
- Paris Brain Institute, Sorbonne University - ICM, Inserm CNRS, Paris, F-75013, France
- Department of Neurology, Clinical Investigation Center for Neurosciences, Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Paris, France
| | - Emmanuel Roze
- Paris Brain Institute, Sorbonne University - ICM, Inserm CNRS, Paris, F-75013, France
- Department of Neurology, Clinical Investigation Center for Neurosciences, Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Paris, France
| | - Yulia Worbe
- Paris Brain Institute, Sorbonne University - ICM, Inserm CNRS, Paris, F-75013, France.
- Department of Neurology, Clinical Investigation Center for Neurosciences, Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Paris, France.
- Department of Neurophysiology, Saint-Antoine Hospital, Paris, France.
| |
Collapse
|
3
|
Liu C, Lan C, Chen Y. The use of sertraline to treat an adolescent of dystonia comorbid with major depressive disorder with psychotic features. Neuropsychopharmacol Rep 2024; 44:275-279. [PMID: 37987035 PMCID: PMC10932769 DOI: 10.1002/npr2.12401] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2023] [Revised: 10/21/2023] [Accepted: 11/04/2023] [Indexed: 11/22/2023] Open
Abstract
Dystonia is characterized by sustained or intermittent involuntary muscle contractions. Psychiatric symptoms are essential non-motor features of dystonia, and higher risks of depressive and anxiety disorders have been reported. The precedence of psychiatric to motor symptoms in some patients and the dopaminergic and serotonergic system involvement in both the motor and psychiatric aspects suggest these psychiatric disorders may be intrinsic to the neurobiology of dystonia. Nevertheless, psychiatric comorbidities are often construed as secondary reactions to motor disabilities and the negative bio-psycho-social impacts of dystonia, leading to underdiagnosis and undertreatment. Research on antidepressant use in dystonia is scarce, especially in children and adolescents. This report presents a 17-year-old female with dystonia comorbid with depression with psychotic features, whose motor symptoms improved but psychiatric symptoms persisted with dopaminergic pharmacotherapy. Sertraline was finally added 5 years after the onset and successfully managed her psychotic depression without worsening motor symptoms. Early detection, prompt diagnosis, and timely holistic treatment with dopaminergic agents, antidepressants, and psychosocial interventions are critical for the mental health of dystonia patients.
Collapse
Affiliation(s)
- Chia‐Chien Liu
- Department of PsychiatryTaichung Veterans General HospitalTaichungTaiwan
| | - Chen‐Chia Lan
- Department of PsychiatryTaichung Veterans General HospitalTaichungTaiwan
| | - Ying‐Sheue Chen
- Department of PsychiatryTaipei Veterans General HospitalTaipeiTaiwan
- Department of PsychiatryChina Medical University HospitalTaichungTaiwan
| |
Collapse
|
4
|
Pringsheim T, Batla A, Shalash A, Sahu JK, Cosentino C, Ebrahimi‐Fakhari D, Friedman J, Lin J, Mink J, Munchau A, Munoz D, Nardocci N, Perez‐Dueñas B, Sardar Z, Triki C, Ben‐Pazi H, Silveira‐Moriyama L, Troncoso‐Schifferli M, Hoshino K, Dale RC, Fung VS, Kurian MA, Roze E. Transitional Care for Young People with Movement Disorders: Consensus-Based Recommendations from the MDS Task Force on Pediatrics. Mov Disord Clin Pract 2023; 10:748-755. [PMID: 37205244 PMCID: PMC10186998 DOI: 10.1002/mdc3.13728] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2022] [Revised: 02/25/2023] [Accepted: 03/05/2023] [Indexed: 05/21/2023] Open
Abstract
Background The International Parkinson and Movement Disorders Society (MDS) set up a working group on pediatric movement disorders (MDS Task Force on Pediatrics) to generate recommendations to guide the transition process from pediatrics to adult health care systems in patients with childhood-onset movement disorders. Methods To develop recommendations for transitional care for childhood onset movement disorders, we used a formal consensus development process, using a multi-round, web-based Delphi survey. The Delphi survey was based on the results of the scoping review of the literature and the results of a survey of MDS members on transition practices. Through iterative discussions, we generated the recommendations included in the survey. The MDS Task Force on Pediatrics were the voting members for the Delphi survey. The task force members comprise 23 child and adult neurologists with expertise in the field of movement disorders and from all regions of the world. Results Fifteen recommendations divided across four different areas were made pertaining to: (1) team composition and structure, (2) planning and readiness, (3) goals of care, and (4) administration and research. All recommendations achieved consensus with a median score of 7 or greater. Conclusion Recommendations on providing transitional care for patients with childhood onset movement disorders are provided. Nevertheless several challenges remain in the implementation of these recommendations, related to health infrastructure and the distribution of health resources, and the availability of knowledgeable and interested practitioners. Research on the influence of transitional care programs on outcomes in childhood onset movement disorders is much needed.
Collapse
Affiliation(s)
- Tamara Pringsheim
- Department of Clinical NeurosciencesPsychiatry, Pediatrics and Community Health Sciences, University of CalgaryCalgaryABCanada
| | - Amit Batla
- Department of Clinical and Movement NeuroscienceUCL Queen Square Institute of NeurologyLondonUK
| | - Ali Shalash
- Department of NeurologyFaculty of medicine, Ain Shams UniveristyCairoEgypt
| | - Jitendra Kumar Sahu
- Pediatric Neurology Unit, Postgraduate Institute of Medical Education and ResearchChandigarhIndia
| | - Carlos Cosentino
- Department of Neurodegenerative DiseasesInstituto Nacional de Ciencias Neurologicas and School of Medicine, Universidad Nacional Mayor de San MarcosLimaPeru
| | | | - Jennifer Friedman
- Departments of Neurosciences and PediatricsUC San DiegoSan DiegoCAUSA
| | - Jean‐Pierre Lin
- Children's Neurosciences, Complex Motor Disorders Service (CMDS)Evelina London Children's Hospital, Guy's and St Thomas’ NHS Foundation Trust (GSTT), and Women and Children's Health Institute Faculty of Life Sciences & Medicine, Kings Health Partners, King's College LondonLondonUK
| | - Jonathan Mink
- Department of NeurologyUniversity of RochesterRochesterNYUSA
| | - Alexander Munchau
- Institute of Systems Motor Science, University of LübeckLübeckGermany
| | - Daniela Munoz
- Department of Paediatric NeurologySan Borja Arriaran Hospital. University of ChileSantiagoChile
| | - Nardo Nardocci
- Pediatric Neuroscience DepartmentFondazione IRCCS Istituto Neurologico “C Besta”MilanItaly
| | - Belen Perez‐Dueñas
- Department of Pediatric NeurologyHospital Universitari Vall d'Hebrón, Universitat Autònoma de Barcelona. Centre for Biomedical Research of Rare Diseases (CIBERER), ISCIIIMadridSpain
| | - Zomer Sardar
- FCPS, Department of NeurologyColumbia University Irving Medical Center/New York Presbyterian HospitalNew YorkNYUSA
| | - Chahnez Triki
- Department of child neurologyHedi Chaker Hospital, LR10ES15, Sfax Medical School, University of Sfax TunisiaSfaxTunisia
| | | | | | | | - Kyoko Hoshino
- Segawa Memorial Neurological Clinic for ChildrenTokyoJapan
| | - Russell C. Dale
- Children's Hospital at Westmead Clinical School, University of SydneySydneyNSWAustralia
| | - Victor S.C. Fung
- Movement Disorders Unit, Department of NeurologyWestmead Hospital & Sydney Medical School, University of SydneySydneyNSWAustralia
| | - Manju A. Kurian
- Developmental NeurosciencesZayed Centre for Research into Rare Disease in Children, GOS‐Institute of Child Health, UCLLondonUK
| | - Emmanuel Roze
- Sorbonne UniversityParis Brain Institute, Assistance Publique—Hôpitaux de Paris, DMU NeurosciencesParisFrance
| |
Collapse
|
5
|
Kyle K, Bordelon Y, Venna N, Linnoila J. Autoimmune and Paraneoplastic Chorea: A Review of the Literature. Front Neurol 2022; 13:829076. [PMID: 35370928 PMCID: PMC8972589 DOI: 10.3389/fneur.2022.829076] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2021] [Accepted: 02/22/2022] [Indexed: 01/17/2023] Open
Abstract
Autoimmune chorea syndromes represent a vast array of paraneoplastic, parainfectious and idiopathic disorders. It is increasingly apparent that familiarity with these disorders is critically important, as they may be treatable or may be part of a syndrome requiring further work-up and monitoring. These disorders are mediated by an aberrant immunologic attack with resultant neuronal dysfunction, manifesting as chorea. These conditions are typically accompanied by other neurologic or systemic manifestations. In this review we outline the clinical features, epidemiologic factors, and delineate the specific antibodies associated with each of these autoimmune mediated disorders. We highlight up to date information regarding this heterogeneous group of disorders, including a discussion of parainfectious Sydenham's chorea; paraneoplastic syndromes associated with CRMP-5 (collapsin response mediated protein-5/CV2) and ANNA-1 (antineuronal nuclear antibody / Hu) antibodies, in addition to neuronal antibody-associated disorders including anti-NMDAR, LGI1 (leucine-rich glioma inactivated-1) and CASPR2 (contactin associated protein-2). We discuss the more recently described entities of IgLON5, which has evidence of both immunologic and degenerative pathophysiology, in addition to PDE-10A antibody-associated chorea. We also outline chorea secondary to systemic diseases including Systemic Lupus Erythematosus (SLE) and Primary Antiphospholipid Syndrome (PAPS). We provide a framework for diagnosis and treatment.
Collapse
Affiliation(s)
- Kevin Kyle
- Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States
- *Correspondence: Kevin Kyle
| | - Yvette Bordelon
- Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, United States
| | - Nagagopal Venna
- Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States
| | - Jenny Linnoila
- Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States
| |
Collapse
|
6
|
Garone G, Graziola F, Grasso M, Capuano A. Acute Movement Disorders in Childhood. J Clin Med 2021; 10:jcm10122671. [PMID: 34204464 PMCID: PMC8234395 DOI: 10.3390/jcm10122671] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2021] [Revised: 06/11/2021] [Accepted: 06/14/2021] [Indexed: 12/14/2022] Open
Abstract
Acute-onset movement disorders (MDs) are an increasingly recognized neurological emergency in both adults and children. The spectrum of possible causes is wide, and diagnostic work-up is challenging. In their acute presentation, MDs may represent the prominent symptom or an important diagnostic clue in a broader constellation of neurological and extraneurological signs. The diagnostic approach relies on the definition of the overall clinical syndrome and on the recognition of the prominent MD phenomenology. The recognition of the underlying disorder is crucial since many causes are treatable. In this review, we summarize common and uncommon causes of acute-onset movement disorders, focusing on clinical presentation and appropriate diagnostic investigations. Both acquired (immune-mediated, infectious, vascular, toxic, metabolic) and genetic disorders causing acute MDs are reviewed, in order to provide a useful clinician’s guide to this expanding field of pediatric neurology.
Collapse
Affiliation(s)
- Giacomo Garone
- Movement Disorders Clinic, Department of Neurosciences, Bambino Gesù Children’s Hospital, IRCCS, viale San Paolo 15, 00146 Rome, Italy; (G.G.); (F.G.); (M.G.)
- University Department of Pediatrics, Bambino Gesù Children’s Hospital, 00165 Rome, Italy
| | - Federica Graziola
- Movement Disorders Clinic, Department of Neurosciences, Bambino Gesù Children’s Hospital, IRCCS, viale San Paolo 15, 00146 Rome, Italy; (G.G.); (F.G.); (M.G.)
| | - Melissa Grasso
- Movement Disorders Clinic, Department of Neurosciences, Bambino Gesù Children’s Hospital, IRCCS, viale San Paolo 15, 00146 Rome, Italy; (G.G.); (F.G.); (M.G.)
| | - Alessandro Capuano
- Movement Disorders Clinic, Department of Neurosciences, Bambino Gesù Children’s Hospital, IRCCS, viale San Paolo 15, 00146 Rome, Italy; (G.G.); (F.G.); (M.G.)
- Correspondence:
| |
Collapse
|
7
|
Lorentzos MS, Heyman I, Baig BJ, Coughtrey AE, McWilliams A, Dossetor DR, Waugh MC, Evans RA, Hollywood J, Burns J, Menezes MP, Mohammad SS, Grattan-Smith P, Gorman KM, Crowe BHA, Goodman R, Kurian MA, Dale RC. Psychiatric comorbidity is common in dystonia and other movement disorders. Arch Dis Child 2021; 106:62-67. [PMID: 32709686 DOI: 10.1136/archdischild-2020-319541] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/30/2020] [Revised: 06/08/2020] [Accepted: 06/15/2020] [Indexed: 12/26/2022]
Abstract
OBJECTIVE To determine rates of psychiatric comorbidity in a clinical sample of childhood movement disorders (MDs). DESIGN Cohort study. SETTING Tertiary children's hospital MD clinics in Sydney, Australia and London, UK. PATIENTS Cases were children with tic MDs (n=158) and non-tic MDs (n=102), including 66 children with dystonia. Comparison was made with emergency department controls (n=100), neurology controls with peripheral neuropathy or epilepsy (n=37), and community controls (n=10 438). INTERVENTIONS On-line development and well-being assessment which was additionally clinically rated by experienced child psychiatrists. MAIN OUTCOME MEASURES Diagnostic schedule and manual of mental disorders-5 criteria for psychiatric diagnoses. RESULTS Psychiatric comorbidity in the non-tic MD cohort (39.2%) was comparable to the tic cohort (41.8%) (not significant). Psychiatric comorbidity in the non-tic MD cohort was greater than the emergency control group (18%, p<0.0001) and the community cohort (9.5%, p<0.00001), but not the neurology controls (29.7%, p=0.31). Almost half of the patients within the tic cohort with psychiatric comorbidity were receiving medical psychiatric treatment (45.5%) or psychology interventions (43.9%), compared with only 22.5% and 15.0%, respectively, of the non-tic MD cohort with psychiatric comorbidity. CONCLUSIONS Psychiatric comorbidity is common in non-tic MDs such as dystonia. These psychiatric comorbidities appear to be under-recognised and undertreated.
Collapse
Affiliation(s)
| | - Isobel Heyman
- Department of Child and Adolescent Mental Health, Great Ormond Street Hospital For Children NHS Foundation Trust, London, UK
| | - Benjamin J Baig
- Department of Child and Adolescent Mental Health, Great Ormond Street Hospital For Children NHS Foundation Trust, London, UK
| | | | - Andrew McWilliams
- Department of Child and Adolescent Mental Health, Great Ormond Street Hospital For Children NHS Foundation Trust, London, UK
| | - David R Dossetor
- Children's Hospital at Westmead, Westmead, New South Wales, Australia
| | - Mary-Clare Waugh
- Kids Rehabilitation Department, The Children's Hospital at Westmead, Sydney, New South Wales, Australia
| | - Ruth A Evans
- Children's Hospital at Westmead, Westmead, New South Wales, Australia
| | - Josie Hollywood
- Department of Child and Adolescent Mental Health, Great Ormond Street Hospital For Children NHS Foundation Trust, London, UK
| | - Joshua Burns
- The University of Sydney, Sydney, New South Wales, Australia
| | - Manoj P Menezes
- Children's Hospital at Westmead, Westmead, New South Wales, Australia
| | | | | | - Kathleen M Gorman
- Department of Neurology and Clinical Neurophysiology, Children's Health Ireland at Temple Street, Dublin, Ireland.,University College Dublin School of Medicine and Medical Science, Dublin, Ireland
| | - Belinda H A Crowe
- The Neurodisability Service, Great Ormond Street Hospital fro Children, London, UK
| | - Robert Goodman
- Child and Adolescent Psychiatry, Institute of Psychiatry, London, UK
| | - Manju A Kurian
- Neurosciences, UCL-Institute of Child Health, London, UK
| | - Russell C Dale
- Children's Hospital at Westmead, Westmead, New South Wales, Australia .,The University of Sydney, Sydney, New South Wales, Australia
| |
Collapse
|
8
|
McGovern E, Pringsheim T, Medina A, Cosentino C, Shalash A, Sardar Z, Fung VSC, Kurian MA, Roze E. Transitional Care for Young People with Neurological Disorders: A Scoping Review with A Focus on Patients with Movement Disorders. Mov Disord 2020; 36:1316-1324. [PMID: 33200525 DOI: 10.1002/mds.28381] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2020] [Revised: 10/14/2020] [Accepted: 10/21/2020] [Indexed: 12/12/2022] Open
Abstract
Childhood-onset movement disorders represent a heterogenous group of conditions. Given the complexity of these disorders, the transition of care from pediatric to adult medicine is an important consideration. We performed a scoping review of the literature on transitional care in chronic neurological disease, exploring key transitional issues and proposed transitional care models. Our aim was to describe the current knowledge and gaps about the transition process of young adults with chronic neurological disorders, paying special attention to childhood onset movement disorders. A total of 64 articles were included in the qualitative synthesis; 56 articles reported on transitional care issues, and 8 articles reported on transitional care models. Only 2 articles included patients with movement disorders. The following 4 main transitional issues were identified following synthesis of the available literature: (1) inadequate preparation for the transition process, (2) inappropriate and inconsistent transition practices, (3) inadequate adult services, and (4) heightened emotional response surrounding transition. Of the reported transitional care models, multidisciplinary ambulatory care was the most common approach. In studies evaluating patient-related outcomes, positive health, educational, and vocational outcomes were found. The available literature provides insights on issues that can arise during transition that should be addressed to improve patient and caregiver comfort and satisfaction with care. Further research is needed to evaluate how transitional care programs affect outcomes and their cost effectiveness. More studies are required to determine the needs and outcomes specific to patients with childhood onset movement disorders. © 2020 International Parkinson and Movement Disorder Society.
Collapse
Affiliation(s)
- Eavan McGovern
- Dublin Neurological Institute, Mater University Hospital, Dublin, Ireland
| | - Tamara Pringsheim
- Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada
| | - Alex Medina
- Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada
| | | | - Ali Shalash
- Department of Neurology, Faculty of Medicine, Ain Shams University, Cairo, Egypt
| | - Zomer Sardar
- Department of Neurology, Mayo Hospital, Lahore, Pakistan
| | - Victor S C Fung
- Movement Disorders Unit, Department of Neurology, Westmead Hospital & Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia
| | | | - Emmanuel Roze
- Department of Neurology, Salpêtrière Hospital, Sorbonne University and Assistance Publique - Hôpitaux de Paris, Paris, France
| | | |
Collapse
|
9
|
Thiels C, Stahl A, Saft C, Juckel G, Lücke T. [Huntington's disease with childhood and adolescent onset: course of disease, clinical presentation and diagnostic challenges]. FORTSCHRITTE DER NEUROLOGIE-PSYCHIATRIE 2020; 88:661-667. [PMID: 32369858 DOI: 10.1055/a-1082-6605] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
Huntington's disease (HD) is an autosomal-dominant neurodegenerative disorder caused by a gene mutation in chromosome 4 that leads to an expansion of CAG - triplet repeats. It occurs mainly between the age of 30 and 50. Only less than 10 % of HD patients are younger than 20 years. In contrast to adult patients young HD patients show more often psychiatric and cognitive symptoms at disease onset than chorea. One third of the children with HD develops an epilepsy.We present 6 children diagnosed with HD in different stages of childhood. We describe first symptoms as well as genetic characteristics and other distinctive features.Both, the clinical presentation and the course of HD in childhood differ from HD in adults. In adolescents the clinical symptoms at onset are often psychiatric (like depression or attention deficit disorder). Choreatic movements typical for adult HD patients are missing.Due to the low prevalence of HD in childhood and the variability of clinical symptoms the process of diagnosing HD in children is difficult. Very often the diagnosis is made years after the first symptoms. Early diagnosis, however, is often important for managing social problems and problems in school.
Collapse
Affiliation(s)
- Charlotte Thiels
- Neuropädiatrie und Sozialpädiatrie, Universitätsklinik für Kinder- und Jugendmedizin der Ruhr-Universität Bochum
| | - Anna Stahl
- Universitätsklinik für Kinder- und Jugendmedizin der Ruhr-Universität Bochum
| | - Carsten Saft
- Abteilung für Neurologie der Ruhr-Universität Bochum, Huntington-Zentrum NRW, St. Josef-Hospital
| | - Georg Juckel
- LWL Klinik für Psychiatrie, Ruhr-Universität Bochum
| | - Thomas Lücke
- Neuropädiatrie und Sozialpädiatrie, Universitätsklinik für Kinder- und Jugendmedizin der Ruhr-Universität Bochum
| |
Collapse
|
10
|
Wilson's Disease in Children: A Position Paper by the Hepatology Committee of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2018; 66:334-344. [PMID: 29341979 DOI: 10.1097/mpg.0000000000001787] [Citation(s) in RCA: 127] [Impact Index Per Article: 18.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
BACKGROUND Clinical presentations of Wilson's disease (WD) in childhood ranges from asymptomatic liver disease to cirrhosis or acute liver failure, whereas neurological and psychiatric symptoms are rare. The basic diagnostic approach includes serum ceruloplasmin and 24-hour urinary copper excretion. Final diagnosis of WD can be established using a diagnostic scoring system based on symptoms, biochemical tests assessing copper metabolism, and molecular analysis of mutations in the ATP7B gene. Pharmacological treatment is life-long and aims at removal of copper excess by chelating agents as D-penicillamine, trientine, or inhibition of intestinal copper absorption with zinc salts. Acute liver failure often requires liver transplantation. This publication aims to provide recommendations for diagnosis, treatment, and follow-up of WD in children. METHODS Questions addressing the diagnosis, treatment, and follow-up of WD in children were formulated by a core group of ESPGHAN members. A systematic literature search on WD using MEDLINE, EMBASE, Cochrane Database from 1990 to 2016 was performed focusing on prospective and retrospective studies in children. Quality of evidence was assessed according to the GRADE system. Expert opinion supported recommendations where the evidence was regarded as weak. The ESPGHAN core group and ESPGHAN Hepatology Committee members voted on each recommendation, using the nominal voting technique.
Collapse
|
11
|
Abstract
Chorea, a movement disorder characterised by a continuous flow of unpredictable muscle contractions, has a myriad of genetic and non-genetic causes. Although autoimmune processes are rare aetiology of chorea, they are relevant both for researchers and clinicians. The aim of this article is to provide a review of the epidemiology, clinical and laboratory features, pathogenesis and management of the most common autoimmune causes of chorea. Emphasis is given particularly to Sydenham's chorea, systemic lupus erythematosus, primary antiphospolipid antibody syndrome, paraneoplastic chorea and anti-N-methyl-d-aspartate receptor encephalitis.
Collapse
|
12
|
Gregorowski C, Lochner C, Martin L, Simmons C, Kidd M, Walker K, Wilmshurst JM, Seedat S. Neuropsychological manifestations in children with Sydenham's chorea after adjunct intravenous immunoglobulin and standard treatment. Metab Brain Dis 2016; 31:205-12. [PMID: 25987537 DOI: 10.1007/s11011-015-9681-1] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/26/2015] [Accepted: 05/05/2015] [Indexed: 10/23/2022]
Abstract
This was an exploratory study comparing neuropsychological manifestations of Sydenham's chorea (SC), 6 months after initiation of treatment, in children who had received intravenous immunoglobulins as an adjunct to standard treatment, with those who had received standard treatment. We included a non-SC control group for comparison. We hypothesized that compared to controls, children with SC who had received prior intravenous immunoglobulins would demonstrate less pronounced impairments compared to those who had received standard care. We conducted a cross-sectional analysis of 17 children with -SC who had received treatment 6 months previously (9 treated with standard of care and 8 augmented with intravenous immunoglobulins) and 17 non-SC, medically well controls. The standard treatment group (n = 9) exhibited significant behavioral difficulties, including significantly poorer co-operation (p = 0.009) compared with the other augmented immunoglobulins and non-SC control groups, and increased impulsivity (p = 0.016) compared with non-SC controls. The standard treatment group scored significantly lower than the other two groups on a measure of executive functioning (p = 0.03). Children with SC may be more at risk for neuropsychological difficulties than non-SC, medically well children. Intravenous immunoglobulins may mitigate some of these impairments.
Collapse
Affiliation(s)
- Claire Gregorowski
- Department of Psychiatry, University of Stellenbosch, P.O. Box 19063, Tygerberg, 7505, South Africa
| | - Christine Lochner
- US/UCT MRC Unit on Anxiety & Stress Disorders, Department of Psychiatry, University of Stellenbosch, Tygerberg, South Africa
| | - Lindi Martin
- Department of Psychiatry, University of Stellenbosch, P.O. Box 19063, Tygerberg, 7505, South Africa
| | - Candice Simmons
- Department of Psychiatry, University of Stellenbosch, P.O. Box 19063, Tygerberg, 7505, South Africa.
| | - Martin Kidd
- Centre for Statistical Consultation, Department of Statistics & Actuarial science, University of Stellenbosch, Tygerberg, South Africa
| | - Kathleen Walker
- Department of Paediatric Neurology, Red Cross War Memorial Children's Hospital, School of Child and Adolescent Health, University of Cape Town, Cape Town, South Africa
| | - Jo M Wilmshurst
- Department of Paediatric Neurology, Red Cross War Memorial Children's Hospital, School of Child and Adolescent Health, University of Cape Town, Cape Town, South Africa
| | - Soraya Seedat
- Department of Psychiatry, University of Stellenbosch, P.O. Box 19063, Tygerberg, 7505, South Africa
- US/UCT MRC Unit on Anxiety & Stress Disorders, Department of Psychiatry, University of Stellenbosch, Tygerberg, South Africa
| |
Collapse
|